What is Sales and Marketing Strategy of Weigao Group Company?

In China, Weigao's sales network covers more than 30 provinces and municipalities. As of December 31, 2024, the company served 10,166 entities, including 3,998 hospitals and 419 blood stations. The addition of 196 new hospitals and 174 new distributors in 2024 underscores a continuous effort to broaden its direct sales and distribution capabilities.

Leveraging its manufacturing strengths and cost efficiencies, Weigao actively participates in volume-based procurement (VBP) initiatives. This strategy has driven steady sales growth, with care consumables experiencing a 5%-15% increase in 2024, demonstrating effective market penetration through competitive pricing and consistent supply.

Internationally, Weigao has significantly expanded its reach, with overseas market revenue reaching RMB 1.72 billion in the first half of 2024, a 6.7% year-on-year increase. Export products saw growth exceeding 20% year-on-year, reflecting a successful international sales approach.

The establishment of the Weigao Overseas Management Group in 2023 has streamlined export operations. The company's global strategy, aiming for 25 strategic hubs by 2025, integrates R&D across continents and focuses on localized operations. This expansion includes strategic partnerships with major global entities and acquisitions that enhance technological capabilities and market access in regions like the United States and the European Union.

The company's brand identity is built on a foundation of human health and social well-being. This is clearly communicated through its mission statement and core values, emphasizing ethical practices.

Weigao aims to be a leader in technologically advanced, branded medical products. It strives to offer world-class quality at competitive production costs, a key differentiator in its market approach.

The company attracts healthcare providers with an expansive product range exceeding 1,000 types of medical devices and pharmaceuticals. This vast offering covers numerous clinical areas, demonstrating its comprehensive capabilities.

Weigao highlights its strong research and development, evidenced by multiple R&D centers and collaborations. In 2024 alone, the company secured 150 new product registration certificates and 127 patents, reinforcing its image as an innovation-driven enterprise.

A core element of Weigao Group's current strategy is its intensified internationalization. The 2025 Global Partner Conference in Shanghai, themed 'CLOSER, TOGETHER, FUTURES,' aimed to foster global expansion by introducing the 'Technology-Capacity-Service' Triangle Model. This shifts focus from mere product export to an 'ecosystem export,' exemplified by the launch of the Greater Hongqiao Medical Device Ecosystem.

Weigao Group actively pursues growth through product diversification and market penetration in high-demand areas. Their orthopedic division, for instance, saw a remarkable 97.49% year-on-year growth in net profit in 2024, with revenue climbing 13.14% to 1.452 billion RMB. This success is driven by strong performance in spine, joint, and trauma products, alongside doubled sales in sports medicine and artificial bone products.

Participation in major international exhibitions is a key marketing initiative to enhance brand visibility and credibility. Following their presence at MEDICA 2024 in Germany, the company is set to exhibit at Arab Health in 2025. These platforms are crucial for highlighting new product launches across orthopedics, interventional devices, hemodialysis, and IVD, fostering partnerships with global healthcare professionals.

The overarching objective of these campaigns is to establish a robust global presence by integrating R&D, production, logistics, legal compliance, and market promotion. This comprehensive approach aims to facilitate seamless international expansion, support mutual recognition of medical standards, and enable cross-border R&D data sharing, reflecting a sophisticated Target Market of Weigao Group approach.